Related Experiment Videos
[Distal spleno-caval shunt in 66 patients with portal hypertension]
1Hepatobiliary Surgery Center, Southwestern Hospital, Third Military Medical University, Chongqing 400038.
Insights
Distal splenocaval shunt surgery effectively manages portal hypertension with a low rebleeding rate and good long-term survival. This procedure is a viable option for patients exhibiting hepatopetal portal flow.
Area of Science:
- Gastroenterology
- Surgical Gastroenterology
- Hepatology
Context:
- Portal hypertension is a serious complication of liver disease.
- Distal splenocaval shunt is a surgical option to manage portal hypertension.
- Evaluating long-term outcomes is crucial for surgical interventions.
Purpose:
- To assess the long-term efficacy and safety of distal splenocaval shunt.
- To report the operative experience and outcomes in a cohort of patients.
- To determine the suitability of this shunt for specific patient profiles.
Summary:
- A cohort of 66 portal hypertension patients underwent distal splenocaval shunt.
- The study reports a 7.58% operative mortality and a similar rate of recurrent bleeding.
- Five-year survival reached 70.45% with no cases of hepatic encephalopathy.
Impact:
- Distal splenocaval shunt demonstrates favorable long-term results for portal hypertension.
- The procedure is particularly suitable for patients with hepatopetal portal flow.
- This study contributes valuable data on the management of portal hypertension via shunting procedures.
Objective:
To evaluate the long-term results and operative experience of distal splenocaval shunt.
Method:
66 patients with portal hypertension were treated by distal spleno-caval shunt. Of these patients 57 were males and 9 females with a mean age of 39 years. All the patients were followed up.
Result:
The operative mortality rate was 7.58%. Only 5 patients experienced recurrent bleeding (7.58%). None of the patients had clinical hepatic encephalopathy. Five-year survival rate was 70.45%.
Conclusion:
Distal splenocaval shunt is suitable for portal hypertension patients with hepatopetal portal flow.